Manager × security

Patient Square Capital LP ROIV holdings history

Who else holds this security? →

ROIVANT SCIENCES LTD · CUSIP G76279101 · CIK 1819257

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Patient Square Capital LP reported 8.02M ROIV (shares), valued at $283.86M, or 43.97% of its reported non-derivative portfolio. Filed 2026-08-12.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
43.97%
Shares
8.02M
8,020,928
Reported value
$283.86M
USD

Shares decreased 1.78%; reported value increased 25.49%, and weight changed +3.84 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202643.97%8,020,928SEC filing ↗Filed Aug 12, 2026
Q1 202640.13%8,166,047SEC filing ↗Filed May 15, 2026
Q4 202537.93%8,166,047SEC filing ↗Filed Feb 12, 2026
Q3 202550.51%12,480,000SEC filing ↗Filed Nov 10, 2025
Q2 202550.71%12,480,000SEC filing ↗Filed Aug 11, 2025
Q1 202552.09%12,480,000SEC filing ↗Filed May 14, 2025
Q4 202455.22%12,480,000SEC filing ↗Filed Feb 14, 2025
Q3 202452.38%12,228,465SEC filing ↗Filed Nov 14, 2024
Q2 202459.99%12,228,465SEC filing ↗Filed Aug 13, 2024
Q1 202454.89%12,228,465SEC filing ↗Filed May 14, 2024
Q4 202377.60%12,639,920SEC filing ↗Filed Feb 13, 2024
Q3 202381.13%12,639,920SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 202381.13%12,639,920$147.63MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 202377.60%12,639,920$141.95MShares unchanged; reported value decreased 3.85%, and weight changed -3.53 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2024
Q1 202454.89%12,228,465$128.89MShares decreased 3.26%; reported value decreased 9.20%, and weight changed -22.71 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2024
Q2 202459.99%12,228,465$129.25MShares unchanged; reported value increased 0.28%, and weight changed +5.10 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2024
Q3 202452.38%12,228,465$141.12MShares unchanged; reported value increased 9.18%, and weight changed -7.61 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 202455.22%12,480,000$147.64MShares increased 2.06%; reported value increased 4.62%, and weight changed +2.84 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 202552.09%12,480,000$125.92MShares unchanged; reported value decreased 14.71%, and weight changed -3.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2025
Q2 202550.71%12,480,000$140.65MShares unchanged; reported value increased 11.69%, and weight changed -1.38 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 11, 2025
Q3 202550.51%12,480,000$188.82MShares unchanged; reported value increased 34.25%, and weight changed -0.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 10, 2025
Q4 202537.93%8,166,047$177.20MShares decreased 34.57%; reported value decreased 6.15%, and weight changed -12.58 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2026
Q1 202640.13%8,166,047$226.20MShares unchanged; reported value increased 27.65%, and weight changed +2.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 202643.97%8,020,928$283.86MShares decreased 1.78%; reported value increased 25.49%, and weight changed +3.84 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2026
Patient Square Capital LP · ROIVANT SCIENCES LTD

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1819257","quarter":"2026Q2","cusip":"G76279101"}

get_institutional_manager_history
{"cik":"1819257","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.